Tracers / [225Ac]Ac-FAPI-46
[225Ac]Ac-FAPI-46
Also written as FAPI-46
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- FAP inhibitor (FAPI)-based small molecule
- Target / mechanism
- Fibroblast activation protein (FAP) PMID 42242868
- Clinical application
- —
- Theranostic pair
- <a href="/tracers/ga68-fapi46/">ga68-fapi46</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | FAPI-46 | 42242868 2026 J Nucl Med |
Need this precursor?We can point you to suppliers for [225Ac]Ac-FAPI-46, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. Compound class inferred from precursor name (not stated outright) -- PMID 42242868: 'FAP inhibitor (FAPI)–46 was radiolabeled with 68Ga for imaging and 225Ac or 177Lu for therapy'. Stage set/updated at stage 23 from PMID 42242868: 'Tumor uptake, therapeutic efficacy, immunomodulatory effects, and survival were evaluated for FAPI-46 alone or in combination with temozolomide in preclinical studies.'.